Zymeworks (ZYME) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.62
- Estimate
- -$0.58
- Surprise
- -6.6%
- Revenue (period 2026-06-30)
- $4.6M
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
Zymeworks (ZYME) reported a wider loss than forecast — diluted EPS of -$0.62 against the -$0.58 estimate (a 6.6% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZYME Sell at 5.7/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -6.6% surprise compares with a -135.5% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Counterparty: Jazz
- Concentration risk — Product: zanidatamab (Ziihera)
- Quality below floor (2.2 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.07
- Price target
- $36.32
- Stop
- $24.40
- Upside to target
- +39.3%
- Reward-to-risk
- 3.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
ZYME at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.88B
- P/E (fwd)
- 22.5
- 52-week range
- $15.49–$31.34
- Off 52-week high
- 16.8%
- RSI (14)
- 40
- Volume vs avg
- 1.41×
- Score today
- 5.7/10